contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Direct reference to the Finnish Limited Liability Companies Act (Osakeyhtiölaki | 624/2006 | Lainsäädäntö | Finlex)  Chapter 18 Redemption of minority shares General provisions Section 1 Right and obligation to redeem A person who holds more than nine-tenths of all the shares and votes in the company (redeemer) is entitled to redeem the shares of other shareholders at a fair price. A shareholder whose shares can be redeemed (minority shareholder) has a corresponding right to demand the redemption of their shares.

Well, at least one expert was found there, who even bothered to reply amidst this Friday evening’s hustle and bustle. Many thanks, @Junkbondking !! I also gave my friend a heads-up to stop barking up the wrong tree. This time, the wisdom of the crowd proved its worth. I now feel a bit more confident to start considering possible additional purchases, as I still see quite immense potential here, which is now simultaneously unfolding around the world. It’s unlikely that Osmo and/or perhaps rather the estate, acting as authorized administrators (due to age alone), are aggressively accumulating this with the intention of shorting it. A pleasant weekend to all for gathering strength, with the upcoming new investment week in mind!

Dude, you’re asking that on a Friday afternoon! but yeah, that’s how it goes

Since no exhaustive answer came from any expert writing on the forum, this question, which I found very interesting, bothered me so much that I called an investor friend (who is much better networked than I am). He said he would shake a tree or two and see what falls into his lap, if anything. I also sent him my entire post that I quoted here, from which he can quote directly if needed. This way, one can appeal to a foolish but curious friend without losing face (by asking silly questions). We’ll see if anything exhaustive comes of it. The fact that no one has bothered or been able to answer this as an expert makes me, as a skeptic, lean towards a more unfavorable interpretation for us small investors: A mere 90% of the votes is enough to take over a company. Ownership of shares in terms of total quantity has no significance. I truly hope I am wrong.

Yep, it’s stated quite clearly in a couple of places there: “According to the Companies Act, a shareholder who owns more than nine-tenths of the company’s shares and the voting rights produced by all shares (the redeemer) has the right to redeem the shares of other shareholders at a fair price.” and “The redeemer must promptly notify the company of the creation or cessation of the right and obligation to redeem. The right to redeem arises when a shareholder owns more than 90% of the company’s shares and votes.” And for good measure, the same link:                   Almgren & Sankamo Oy – 1 Apr 22              Osakeyhtiölain mukainen vähemmistöosakkeiden lunastaminen - Almgren &...    Kun jonkun omistajan omistusosuus nousee yli 90 % osakeyhtiössä, syntyy osakeyhtiölain mukainen lunastusoikeus ja –velvollisuus. Osakeyhtiön koolla tai sillä onko kyseessä tavallinen osakeyhtiö ja julkinen osaskeyhtiö (Oyj) ei ole merkitystä...         Est. reading time: 4 minuuttia                               Hey @Antti_Siltanen! As our company’s official analyst, could you kindly confirm that this is indeed the case? That is, the right to redeem minority shares arises (only) when a shareholder owns BOTH more than 90% of the company’s shares (numerically from the entire share capital) AND SIMULTANEOUSLY (most naturally) more than 90% of the votes. Confirmation of this would bring considerable peace of mind to the owner compared to a situation where merely over 90% of voting power would be sufficient to take over the company.

Regarding shares and votes, and when looking at the ownership, redemption/”takeover” can certainly be ruled out.                   Almgren & Sankamo Oy – 1 Apr 22              Osakeyhtiölain mukainen vähemmistöosakkeiden lunastaminen - Almgren &...    Kun jonkun omistajan omistusosuus nousee yli 90 % osakeyhtiössä, syntyy osakeyhtiölain mukainen lunastusoikeus ja –velvollisuus. Osakeyhtiön koolla tai sillä onko kyseessä tavallinen osakeyhtiö ja julkinen osaskeyhtiö (Oyj) ei ole merkitystä...         Est. reading time: 4 minuuttia

Would redemption require 90% of the shares or voting power, or both? Now that there are two classes of shares and the shares with more voting power are almost all held by Suovaniemi and Hefe, Suovaniemi could quite easily acquire 90% of the voting power, perhaps even with a small premium, if Hefe wished to divest its entire ownership.

Biohit

Biohit’s H2 exceeded our expectations in terms of growth and earnings were in line with our forecasts. Revenue growth was supported by positive development in various products and markets.

<p>Biohit’s H2 exceeded our expectations in terms of growth and earnings were in line with our forecasts. Revenue growth was supported by positive development in various products and markets. We raise our revenue growth forecasts with the company’s good track record. We raise our earnings forecasts more moderately due to the increase in cost levels. The valuation picture has remained largely unchanged and the risk/reward ratio of the stock is attractive enough in our opinion to support a Buy recommendation. </p> 

	2023	24e	25e
Revenue	13.1	15.3	17.4
growth-%	19.2 %	16.9 %	14.0 %
EBIT (adj.)	1.8	1.9	2.5
EBIT-% (adj.)	13.4 %	12.5 %	14.2 %
EPS (adj.)	0.12	0.13	0.13
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	16.3	28.0	27.1
EV/EBITDA	11.4	19.5	15.4

Biohit: Growth measures taking effect

Key Estimate Figures2024-02-15

Forum discussions